Gilead Successfully Completes Fourth Phase III Study
"This morning Gilead announced that it has successfully wrapped up positive top-line data from its fourth and last Phase III study for sofosbuvir, putting the biotech on a short path to the FDA with what promises to be the first oral drug for hepatitis C."
To read more please visit: http://www.fiercebiotech.com/story/gilead-races-fda-after-hep-c-blockbuster-hopeful-scores-4th-win-phiii/2013-02-19?utm_medium=nl&utm_source=internal
1300 Wilson Boulevard | Suite 300 | Arlington, VA 22209 | Phone: (703) 299-0200 | Fax: (703) 299-0204
| HIVMA | Contact Us
© Copyright IDSA 2013 Infectious Diseases Society of America